Quick Answer: Philippines FDA cosmetic product requirements connect a valid local establishment licence with product notification, a lawful formula, accurate labelling and an accessible Product Information File. Prepare one consistent technical record for the exact formula, manufacturer, claims and pack. A License to Operate (LTO) covers the establishment; a Certificate of Product Notification (CPN) concerns the product. Neither replaces ongoing responsibility for safety and compliance or constitutes government endorsement.
Start with the exact product and its intended use
A Philippines product review begins with a controlled identity: product name, brand, cosmetic function, format, intended users, application area and directions. Record the manufacturing site and formula revision. This guide addresses technical product readiness; channel strategy and commercial launch planning are separate decisions. A different pack or marketing description can create a new review question even when a supplier describes the bulk formula as unchanged.
Check classification before commissioning final artwork. Cosmetic presentation must fit the intended cosmetic purpose. A message about treating a disease, a pharmaceutical mode of action or an unusual ingredient may require clarification. The FDA notification service checklist expressly provides for additional information where intended use or ingredient origin and safety need verification. The label and advertising should tell the same story as the technical product brief.
Keep unresolved questions in a review log with an owner and a release condition. A foreign product listing, an export certificate or a supplier assurance does not determine the Philippine route. Ask the local regulatory reviewer to assess this product and document the reasoning before the design and manufacturing teams commit to a final version.
| Record | What it addresses | Practical review |
|---|---|---|
| LTO | Licensed local establishment and its activity | Valid licence and appropriate cosmetic activity |
| CPN | Notification of the identified cosmetic product | Correct product, company and submitted particulars |
| PIF | Supporting safety, quality and benefit information | Complete, current and accessible technical evidence |
| Artwork master | Consumer information on the actual pack | Matches formula, warnings and product identity |
Confirm the local establishment and technical handoff
The FDA service checklist identifies a valid LTO with an activity of Cosmetics Manufacturer, Cosmetics Trader or Cosmetics Distributor–Importer. It also identifies the company name, establishment address and LTO number as application information. Verify the activity for the actual supply arrangement. A manufacturer abroad does not become the Philippine licensed establishment simply by supplying a finished product.
Agree who holds the local record, who authorises the submission and who answers FDA questions. The brand should know how its manufacturer will provide confidential composition information, how the local operator will access the evidence and how both will receive updates. Establish a secure method for technical disclosure that still enables a proper review.
Work with the OEM/ODM cosmetics manufacturer on a destination-specific document list. Request controlled files for the actual manufacturing site, formula and packaging system. Generic certificates can support background checks, but they do not by themselves demonstrate the safety or performance of the finished product. Give the manufacturer enough time to resolve missing data before the filing team needs it.
Review ingredients against ASEAN lists and Philippine implementation
Map every raw material to its constituent ingredients, recognised names and intended functions. Record the quantitative composition needed by the reviewer, including the contribution of blends and premixes. Evaluate restricted ingredients using the applicable product category, exposure, maximum concentration, purity conditions and mandatory warnings. A trade name alone is insufficient for this assessment.
The ASEAN framework distinguishes prohibited substances in Annex II, restricted ingredients in Annex III, permitted colourants in Annex IV, preservatives in Annex VI and UV filters in Annex VII. Our ASEAN ingredient restrictions guide helps organise the questions. Use the actual relevant entry and current national implementation rather than treating an ingredient database or an EU listing as permission for the Philippines.
Philippines FDA Circular No. 2026-0001 consolidates amendments from the 40th to 42nd ASEAN Cosmetic Committee meetings. Its national guidelines say that only grace periods specific to the Philippines apply locally; otherwise products on the Philippine market must meet the ACD standards including the circular’s updates. The circular includes differences between regional discussions and national positions. This makes entry-level checking essential.
A June 2026 revision date on another ASEAN authority’s annex collection is a useful regional version signal, but does not independently establish a Philippine commencement date. Check the Philippine circular, the applicable annex entry and any later national issuance together. Preserve the reviewed text and the reviewer’s conclusion. Do not substitute EU limits simply because a meeting discussion cites an EU regulation.
| Check | Required review input | Useful output |
|---|---|---|
| Ingredient identity | Constituent names, composition and identifiers | Resolved identity for each material |
| Regulatory status | Relevant ACD entry and Philippine implementation | Allowed use and conditions recorded |
| Finished concentration | Quantitative formula and blend contributions | Calculation for the actual finished product |
| Consumer information | Entry-specific warnings and use restrictions | Agreed artwork wording and directions |
Prepare the Product Information File before release
Use the FDA’s updated PIF guidelines, filed with the UP Law Center as the national reference for organising product information. A Product Information File is the technical evidence behind the marketed cosmetic. It should allow the responsible establishment and a reviewer to understand the product, assess supporting records and respond to a regulatory request. Our ASEAN PIF requirements guide provides a practical regional introduction.
Organise administrative product information, raw-material quality information, finished-product quality information, and safety and benefit support into a clear index. Distinguish a supplier specification from an actual test result, and a draft report from an approved assessment. Record file revisions and links to the exact formula and packaging version so evidence for an earlier sample is not silently reused for a changed product.
Select testing through a product-specific assessment. Consider microbiological quality, preservation where relevant, physical and chemical stability, packaging compatibility and foreseeable use. An anhydrous product and an aqueous jar cream may have different evidence needs. Avoid making a universal testing package or a single certificate appear sufficient for every format.
The safety review needs reliable information about composition, impurities where relevant, exposure, directions and users. The person assessing safety should be able to identify gaps and explain the basis of the conclusion. Keep the assessment and underlying evidence available through the responsible arrangement; an index that points to inaccessible supplier files is not a workable dossier.
Check the label as a physical consumer document
Prepare a label checklist covering product name and function, directions where needed, ingredient listing, country of manufacture, local responsible company information, net contents, batch identification, durability information and relevant precautions. Determine the precise particulars and placement for the actual pack under current requirements. Do not assume a very small container removes the need for consumer information.
The FDA’s published ASEAN labelling amendments address matters including ingredient order, perfume terminology and durability provisions. These are part of the framework, not a substitute for reviewing the complete current labelling requirements. Have the local reviewer confirm the applicable wording, language and packaging arrangement, including any product-specific warnings introduced by ingredient conditions.
Approve the print proof at realistic size. Check contrast on curved surfaces, ingredient text at folds and seams, batch-code space and the relationship between primary and outer packaging. Retain photographs or a signed proof of the final version. The product identity in the notification, dossier and printed pack should remain consistent.
Review benefit statements with the same discipline. A moisturising claim, a quantified performance claim and a comparison require different supporting evidence. Record which study or assessment supports each material statement and whether its test conditions match the marketed use. Apply the agreed wording to product pages and sales materials as well as the carton.
| Review stage | Technical cross-check | Condition before proceeding |
|---|---|---|
| 1. Copy preparation | Approved formula and naming record | Ingredient identities resolved |
| 2. Technical review | Exposure assessment, annex conditions and claim evidence | Directions, warnings and benefits supported |
| 3. Production proof | Manufacturing codes, pack size and readability | Final physical proof approved |
| 4. Release and retention | Product master and final artwork revision | Dossier and printed version reconciled |
Create one notification dataset and retain the filing trail
The FDA checklist describes a cosmetic portal account, completion of the application and declaration, payment, evaluation and the final result. Confirm the current official instructions for the actual category at the time of filing. A published service checklist is useful for preparation, but should not be treated as proof that every category always follows an identical portal route or processing path.
Prepare one verified dataset before entry: company and LTO details, product identity, manufacturing information and formula particulars requested by the official system. Check spelling, names and site addresses against the underlying documents. Use our ASEAN notification overview for regional context while keeping the Philippines record under local control.
Where the FDA needs clarification, the service checklist identifies possible supporting materials such as mechanism of action, origin information, labelling artwork, instructions, safety data and analysis. These are conditional clarification materials, not a claim that every item is always uploaded for every ordinary notification. The checklist also states that supplying clarification documents does not guarantee issuance.
Keep submitted versions, declarations, transaction references, correspondence and the issued record. Check the final CPN details against the master before relying on it for release. Verify current fees and service expectations directly at filing; this guide does not promise a fee, completion date or automatic outcome. A payment record and an issued CPN are different events.
| Workstream | Manufacturer contribution | Brand and Philippine operator contribution |
|---|---|---|
| Formula control | Accurate composition, site and revision records | Local assessment and reconciled application |
| Quality and safety | Relevant specifications, studies and explanations | Assess gaps and maintain dossier access |
| Artwork | Production proof and pack specification | Approve local particulars and supported claims |
| After launch | Batch investigation and advance change notice | Review local action, complaints and record maintenance |
Maintain readiness when the product changes
Create a change process for formula, raw-material source, manufacturing site, pack, product identity and claims. Assess the effect on safety, quality, labelling, evidence and notification before implementation. A supplier substitution can affect the constituent formula even when the commercial raw-material name appears similar. Record the decision and the effective batch.
Track the actual authorisation dates and current maintenance instructions. Do not assume a CPN remains suitable after a material change or that an establishment licence settles the product record. Keep complaint information connected to product identity and batch so the manufacturer can investigate and the local operator can decide the appropriate action.
A useful final handover includes the approved product master, reviewed artwork, dossier index, notification record, remaining conditions and named contacts. For help organising a manufacturing evidence handoff, contact the project team with the formula status, pack concept and document gaps. Qualified local review remains necessary for the final Philippine decision.
Frequently asked questions
Is an LTO the same as a CPN?
No. The LTO concerns the licensed establishment and its activity. The CPN concerns the notified product. Product evidence, labelling and ongoing compliance remain separate responsibilities.
Does notification mean the FDA endorses the cosmetic?
No. Describe the record accurately as a Certificate of Product Notification. It does not remove the operator’s or manufacturer’s responsibility for safety, quality and supported claims.
Can a formula sold in another ASEAN country be used unchanged?
It still needs a Philippine review. Check ingredient conditions, the exact product category and Philippine implementation of amendments, including applicable transition provisions.
Does every PIF document need to be uploaded for notification?
Do not equate maintaining the technical evidence file with a universal upload requirement. Follow the current official application instructions and provide any clarification documents requested for the case.
What should be checked before printing labels?
Reconcile the exact formula, product identity, directions, responsible company details, batch and durability information, required warnings and evidence for claims. Review the physical print proof and retain the approved version.
Last reviewed: 24 October 2026. General technical planning information only, not product-specific legal or safety advice. Confirm current Philippine requirements and the appropriate action with a qualified local reviewer before notification, manufacture, import or sale.